Condition (MeSH)
Hemoptysis
ClinicalTrials.gov lists 37 trials for Hemoptysis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
37 of the 37 trials are tagged with Hemoptysis itself; the rest are tagged with a narrower condition beneath it.
When did Hemoptysis trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 1 |
| 2023 | 3 |
| 2022 | 7 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 4 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 2 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 37 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemoptysis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 2/3 | 2 |
| Phase 3 | 5 |
| Phase 4 | 2 |
| Not applicable | 12 |
| Observational | 15 |
How many Hemoptysis trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |
| Completed | 21 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemoptysis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Aesculap AG | 1 |
| Lee's Pharmaceutical Limited | 1 |
| National Cancer Institute (NCI) | 1 |
Which drugs are being tested for Hemoptysis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| acid tranexamic | 8 |
| Epinephrin | 3 |
| Radiation Therapy | 2 |
| TXA Nebulization | 1 |
| or carboplatin | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemoptysis trials report? (7)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypoxemic respiratory failure | 5 | 1 |
| Pneumothorax | 3 | 1 |
| Abdominal pain | 1 | 1 |
| Constipation | 1 | 1 |
| Cough | 1 | 1 |
Showing 5 of 7 adverse events.
Which publications cover Hemoptysis? (108)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinically significant hemoptysis and all-cause mortality in patients with nontuberculous mycobacterial pulmonary disease. | Respiratory medicine | 2025 | Yes |
| Efficacy and safety of tranexamic acid nebulization to control bleeding of hemoptysis: The TXA-NEB randomized controlled clinical trial. | Indian journal of pharmacology | 2025 | Yes |
| Hemoptysis and a Newly Formed Lung Bulla in a Case of Convalescent COVID-19 Pneumonia. | Internal medicine (Tokyo, Japan) | 2021 | Yes |
| Long-term prognostic outcomes in patients with haemoptysis. | Respiratory research | 2021 | Yes |
| 2019 Novel Coronavirus (COVID-19) Pneumonia with Hemoptysis as the Initial Symptom: CT and Clinical Features. | Korean journal of radiology | 2020 | Yes |
Showing 5 of 108 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.